您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Azido-PEG4-Val-Cit-PAB-OH
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Azido-PEG4-Val-Cit-PAB-OH
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Azido-PEG4-Val-Cit-PAB-OH图片
规格:98%
分子量:652.74
包装与价格:
包装价格(元)
50mg电议
100mg电议

产品介绍
Azido-PEG4-Val-Cit-PAB-OH 是一种可降解 (cleavable) 的含 4 个单元 PEG 的 ADC linker,可用于合成抗体偶联药物 (ADC)。Azido-PEG4-Val-Cit-PAB-OH 还是一种 PROTAC linker,属于 PEG 类,可用于合成 PROTAC 分子。
货号:ajcx34546
CAS:2055024-64-9
分子式:C29H48N8O9
分子量:652.74
溶解度:N/A
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Azido-PEG4-Val-Cit-PAB-OH is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1]. Azido-PEG4-Val-Cit-PAB-OH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[2].

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].

[1]. Dan N, et al. Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. Pharmaceuticals (Basel). 2018 Apr 9;11(2). pii: E32.
[2]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.